A phase I/II study of Xcellerated T Cells in patients with chronic lymphocytic leukemia

TJ Kipps(Stanford University), Mark W. Frohlich, J. E. Castro, William G. Wierda(University of Maryland, Baltimore), Ronald G. Steis, R. J. Berenson(Fred Hutch Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Julia Meyer(NYU Langone Health)

Journal of Clinical Oncology

June 1, 2005

10.1200/jco.2005.23.16_suppl.2511

Cited by 1

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

|Blood|2008|3.2k

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

|New England Journal of Medicine|2013|2.2k

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

|New England Journal of Medicine|2015|1.9k

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

|Blood|2018|1.7k

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

|Blood|1997|1.2k